To determine more precisely the sequence required for ASF/SF2 binding to the RNA, a short sequence upstream of the proximal splice site was mutated (14 nt) or deleted (11 nt) in a plasmid containing just the terminal part of intron 7 and the proximal part of exon 8

To determine more precisely the sequence required for ASF/SF2 binding to the RNA, a short sequence upstream of the proximal splice site was mutated (14 nt) or deleted (11 nt) in a plasmid containing just the terminal part of intron 7 and the proximal part of exon 8.Fig. RNA immunoprecipitation using VEGF mRNA sequences identified an 11-nucleotide sequence required for ASF/SF2 binding. Injection of an SRPK1/2 inhibitor reduced angiogenesis in a mouse model of retinal neovascularization, suggesting that regulation of alternative splicing could be a potential therapeutic strategy in angiogenic pathologies. Keywords:Growth Factors, RNA/Splicing, ASF/SF2, Angiogenesis, SRPK1, VEGF == Introduction == Vascular endothelial growth factor (VEGF-A, hereafter referred to as VEGF)5is a key regulatory component in physiological and pathological angiogenesis. Inhibition of VEGF has shown to be effective in cancer (1) and ocular angiogenesis (2), and it is up-regulated by a number of growth factors also implicated in these conditions, including insulin-like growth factor-1 (IGF-1) (3). VEGF is generated as multiple isoforms by alternative splicing (4). There are NU 1025 two principal families of VEGF isoforms, the pro-angiogenic VEGFxxxisoforms, generated by proximal splice site selection in the terminal exon, exon 8a (5), and the anti-angiogenic VEGFxxxb isoforms (6), generated by use of a distal splice site 66 bp further into exon 8, NU 1025 generating mRNA isoforms that contain exon 8b. As the stop codon for the protein is encoded in exon 8, these two isoforms contain alternate six amino acids at the C terminus (Fig. 1A). The pro-angiogenic isoforms such as VEGF165encode a terminal six amino acid sequence of CDKPRR, and the anti-angiogenic isoforms such as VEGF165b encode SLTRKD (7). Many normal tissues, including the eye generate both isoforms (8), and previous studies have shown that the anti-angiogenic isoforms dominate in non-angiogenic tissues such as the normal colon (9) and the vitreous (8). However, there is a splicing switch in angiogenic conditions such as proliferative diabetic retinopathy (8), colon (9), prostate (10), renal (7), and skin cancers (11), and in Denys Drash Syndrome (12). In contrast, in non-angiogenic conditions where VEGF is up-regulated, such as glaucoma and rhegmatogenous retinal detachment associated with proliferative vitreoretinopathy (13) or glaucoma (14), the anti-angiogenic isoforms are up-regulated. We have previously shown that IGF-1 can switch splicing in cultured epithelial cells from anti-angiogenic to pro-angiogenic isoforms (15). As IGF-1 has been implicated in a number of angiogenic conditions including diabetic retinopathy and colon cancer, we hypothesized that the mechanism through which IGF-1 mediates this change in splicing may be a potential therapeutic target to prevent angiogenesis. To this end, we have investigated the signaling pathways, the splicing factors involved, and the possibility of therapeutic intervention in the pathway in an animal model of diabetic retinopathy. == FIGURE 1. == Inhibition of PKC by BIM1 prevents the down-regulation of VEGFxxxb by IGF.A, exon structure of the VEGF pre-mRNA. Alternative splicing of exon 8 to either 8a or 8b results in use of proximal (PSS) or distal splice sites (DSS) resulting in shorter mRNA for distal splicing. Because the last stop codon is missing, the final six amino acid open reading frame is replaced by an identically sized open reading frame encoding six different amino acids. The primer position is shown byhorizontal arrows. BD, podocytes were treated with BIM1 (2.5 m) alone or in combination with IGF-1 (100 nm).B, RT-PCR showed that BIM1 reduced the VEGFxxx:VEGFxxxb ratio at the RNA level.C, Western blot demonstrating that BIM1 inhibited the IGF-mediated down-regulation of VEGFxxxb expression at the protein level.D, ELISA results confirming that BIM1 specifically attenuated the IGF-1-dependent down-regulation of VEGFxxxb, but does not impact endogenous manifestation of VEGFxxxb. **,p< 0.01 compared with untreated. == EXPERIMENTAL Methods == == == == == == Proliferating Podocytes == PCIPs (courtesy of Moin Saleem, University or college of Bristol, Bristol, UK) were derived from a cell collection conditionally transformed from normal human podocytes having a temperature-sensitive mutant of immortalized SV-40 T-antigen. In the permissive heat of 33 C, the SV-40 T-antigen is definitely active and allows the cells to proliferate rapidly (16). PCIPs were cultured in T75 flasks (Greiner) in RPMI 1640 medium (Sigma) with 10% fetal bovine serum, 1% ITS (insulin transferrin selenium) (Sigma), 0.5% penicillin-streptomycin solution (Sigma), and produced to 95% confluency. Then cells were Rabbit polyclonal to ACTL8 split into 6-well plates (2 105cells per well) and produced NU 1025 until 95% confluency. == Treatments with IGF-1 and Pharmacological Inhibitors == To investigate the inhibitory effect of IGF-1 on VEGFxxxb mRNA and protein synthesis, pharmacological inhibitors and IGF-1 with PKC-BIMI (Calbiochem), and SRPK1/2 (SR protein kinases 1 and 2)-SRPIN340 (SR protein phosphorylation inhibitor.